

**Monday 10 October 2016**

<b>Session 1: Keynote and Success Stories. CHAIRS: Nathan Fuller (Rodin Therapeutics)</b>			
08:30	Steve Fesik	Vanderbilt	<b>Keynote Lecture: Discovery of Mcl-1 Inhibitors for the Treatment of Cancer</b>
09:15	Izzat Raheem	Merck	Discovery of Pyrazolopyrimidine PDE10A Inhibitors for the Treatment of Schizophrenia Enabled by Fragment Based Lead Discovery
09:45	Scott Cowen	AstraZeneca	Fragment Assisted Design of Novel PIM Inhibitors Aiming for Inhaled Delivery to Treat Severe Asthma
10:15	<b>Coffee</b>		
<b>Session 2: Success Stories. CHAIR: Vickie Tsui (Genentech)</b>			
10:45	Wolfgang Jahnke	Novartis	Fragment-based Discovery of ABL001, an allosteric inhibitor of Bcr-Abl
11:15	Doug Davies	Beryllium	Targeting protein-protein interfaces in Influenza and Ebola viral targets using fragment screening
11:45	Kathy Lee	Pfizer	LEAD GENERATION STRATEGIES: DISCOVERY OF A POTENT, SELECTIVE AND LIPOPHILIC EFFICIENT IRAK4 INHIBITOR, A CLINICAL CANDIDATE FROM FRAGMENT-BASED DRUG DESIGN
12:15	<b>LUNCH + POSTERS + EXHIBITS</b>		
<b>Session 3: Computational. CHAIR: Chris Murray (Astex)</b>			
14:00	Sandor Vajda	Boston University	FRAGMENT BASED PREDICTION OF DRUGGABILITY AND FRAGMENT BINDING
14:30	John Kulp	MetaLeaps, LLC	Boltzmann Fragment Maps used in Lead Identification and Optimization: A review of diverse applications over 10 years
15:00	Chris Radoux	CCDC	Identifying Interactions that Determine Fragment Binding at Protein Hotspots
15:30	Carsten Detering	BioSolveIT	Inhabiting the chemical compound universe: Virtual chemistry 2.0
16:00	<b>Coffee</b>		
<b>Session 4: Methods. CHAIR: Rod Hubbard (Vernalis)</b>			
16:20	Ali Raja	Nanotemper Technologies	Microscale Thermophoresis: Automated Screening of a Fragment Library against MEK1 Kinase
16:50	Julien Orts	ETH Zurich	NMR Molecular Replacement, NMR2
17:20	Bill Marathias	Maratech NMR	NMR Screening Strategies for Targeting microRNAs with Fragments
17:50 - 19:00	posters and exhibitor session - hors d'oeuvres served		

**FREE EVENING**